Refractory IgG Warm Autoimmune Hemolytic Anemia Treated with Eculizumab: A Novel Application of Anticomplement Therapy.

about

Mechanism-Based Strategies for the Management of Autoimmunity and Immune Dysregulation in Primary Immunodeficiencies Anti-CD20 Treatment of Autoimmune Hemolytic Anemia Refractory to Corticosteroids and Azathioprine: A Pediatric Case Report and Mini Review

P2860

Q28066193-21C30532-9CC2-4E49-B3CD-0C6C8888570F Q58702094-452EDEEA-F644-4D4D-B44F-FA8F291F22E4

P2860

Refractory IgG Warm Autoimmune Hemolytic Anemia Treated with Eculizumab: A Novel Application of Anticomplement Therapy.

Item

http://www.wikidata.org/entity/Q39862648

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Refractory IgG Warm Autoimmune ...... ion of Anticomplement Therapy.

@en

Refractory IgG Warm Autoimmune ...... ion of Anticomplement Therapy.

@nl

type

Item

label

Refractory IgG Warm Autoimmune ...... ion of Anticomplement Therapy.

@en

Refractory IgG Warm Autoimmune ...... ion of Anticomplement Therapy.

@nl

prefLabel

Refractory IgG Warm Autoimmune ...... ion of Anticomplement Therapy.

@en

Refractory IgG Warm Autoimmune ...... ion of Anticomplement Therapy.

@nl

P1476

Refractory IgG Warm Autoimmune ...... ion of Anticomplement Therapy.

@en

P2093

Kim Ma

http://www.w3.org/2001/XMLSchema#string

Stephen Caplan

http://www.w3.org/2001/XMLSchema#string

P2860

Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease

Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.

Refractory warm IgM-mediated autoimmune hemolytic anemia associated with Churg-Strauss syndrome responsive to eculizumab and rituximab.

How I treat autoimmune hemolytic anemias in adults.

Paroxysmal nocturnal hemoglobinuria and the age of therapeutic complement inhibition.

Diagnosis and classification of autoimmune hemolytic anemia.

Autoimmune manifestations in patients with Waldenström macroglobulinemia.

Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients.

Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria.

Long-term response of refractory primary cold agglutinin disease to eculizumab therapy.

P304

9181698

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2016/9181698

http://www.w3.org/2001/XMLSchema#string

P478

2016

http://www.w3.org/2001/XMLSchema#string

P577

2016-03-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27092282

http://www.w3.org/2001/XMLSchema#string

P932

4820603

http://www.w3.org/2001/XMLSchema#string

Refractory IgG Warm Autoimmune Hemolytic Anemia Treated with Eculizumab: A Novel Application of Anticomplement Therapy.

about

P2860

P2860

Refractory IgG Warm Autoimmune Hemolytic Anemia Treated with Eculizumab: A Novel Application of Anticomplement Therapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932